As of 01 December 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for IV infusion] and (2) Lenvatinib [4 mg/10 mg capsule] for adults diagnosed with advanced continue reading : HTA Council Preliminary Recommendation on (1) Atezolizumab + Bevacizumab and (2) Lenvatinib for Adults Diagnosed with Advanced or Unresectable Hepatocellular Cancer (HCC)
HTA Council Preliminary Recommendation on Thermal Ablation for the Treatment of Premalignant Lesions of the Cervix among Women 30 to 65 years old
As of 19 November 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of Thermal Ablation for the treatment of premalignant lesions of the cervix among women 30 to 65 years old who are deemed eligible for ablation in accordance to the World Health Organization (WHO) screen-treat approach or screen-triage-treat continue reading : HTA Council Preliminary Recommendation on Thermal Ablation for the Treatment of Premalignant Lesions of the Cervix among Women 30 to 65 years old
HTA Council Preliminary Recommendation on Moderate Complexity Nucleic Acid Amplification Tests (NAAT) for the Diagnosis of Multi-drug Resistant Tuberculosis (MDR-TB) with Simultaneous Isoniazid and Rifampicin Resistance Testing
As of 28 October 2025, the Health Technology Assessment Council has completed the evidence appraisal on the assessment of moderate complexity nucleic acid amplification tests (NAATs) for the diagnosis multi-drug resistant tuberculosis (MDR-TB) with simultaneous isoniazid (INH) and rifampicin (Rif) resistance testing for possible government financing. The HTA Council hereby releases its preliminary recommendation on continue reading : HTA Council Preliminary Recommendation on Moderate Complexity Nucleic Acid Amplification Tests (NAAT) for the Diagnosis of Multi-drug Resistant Tuberculosis (MDR-TB) with Simultaneous Isoniazid and Rifampicin Resistance Testing
HTA Council Preliminary Recommendation on Biannual Ultrasound (US) Combined with Alpha Fetoprotein (AFP) Test for the Screening of Adults at High Risk to Develop Hepatocellular Carcinoma (HCC)
As of 28 October 2025, the Health Technology Assessment (HTA) Council has completed the evidence appraisal on the assessment of Biannual Ultrasound (US) combined with Alpha Fetoprotein (AFP) test as screening test for adults at high risk to develop hepatocellular carcinoma (HCC) for possible government financing. The HTA Council hereby releases its preliminary recommendation on continue reading : HTA Council Preliminary Recommendation on Biannual Ultrasound (US) Combined with Alpha Fetoprotein (AFP) Test for the Screening of Adults at High Risk to Develop Hepatocellular Carcinoma (HCC)
HTA Council Preliminary Recommendation on Rotavirus Vaccine (Live, Attenuated) Monovalent G1P[8] Stain Porcine Circovirus (PCV)- Free for the prevention of Gastroenteritis caused by Rotavirus Infection in Children one (1) year of age
Update as of 11 November 2025 : Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Rotavirus Vaccine (live, attenuated) monovalent G1P[8] strain porcine circovirus (PCV) – free ended on 04 November 2025 without any appeals received, this preliminary HTA Council recommendation lapsed into the Final Recommendation and was transmitted on 11 November 2025 to the Secretary of continue reading : HTA Council Preliminary Recommendation on Rotavirus Vaccine (Live, Attenuated) Monovalent G1P[8] Stain Porcine Circovirus (PCV)- Free for the prevention of Gastroenteritis caused by Rotavirus Infection in Children one (1) year of age